Report Detail

Other U.S. Influenza (Flu) Vaccines Market – Growth, Demand, Trends, Opportunity, Forecasts (2021 – 2028)

  • RnM4347322
  • |
  • 14 October, 2021
  • |
  • Global
  • |
  • 205 Pages
  • |
  • DPI Research
  • |
  • Other

1. Executive Summary

    2. United States Influenza Vaccines Market Size and Forecasts (2015 – 2028)

      3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2028)

      • 3.1 Number of Children Vaccinated with Influenza Vaccines
      • 3.2 Number of Adults Vaccinated with Influenza Vaccines

      4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market

      • 4.1 Market Drivers
      • 4.2 Market Restraints

      5. United States Influenza Vaccines Pricing Trends & Analysis

        6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

          7. United States Influenza Vaccines Distribution & Demand (2010 – 2021)

            8. Effectiveness of Influenza Vaccines in the United States (2004 – 2021)

              9. Rapid Diagnostic Testing for the Management of Influenza

                10. Distribution Channel and Technique of Influenza Vaccination in the United States

                  11. Reimbursement Environment of the United States Influenza Vaccines Market

                    12. Regulatory Framework of the United States Influenza Vaccines Market

                      13. Major Deals and Agreement Happenings in the Influenza Vaccines Market

                      • 13.1 Merger & Acquisitions
                      • 13.2 Collaboration Deal
                      • 13.3 Licensing Agreement
                      • 13.4 Exclusive Agreement
                      • 13.5 Distribution Agreement

                      14. Promising Influenza Vaccines in the Clinical Development

                        15. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country

                        • 15.1 Year 2020
                        • 15.2 Year 2019

                        16. Key Players Analysis

                        • 16.1 Sanofi Pasteur
                          • 16.1.1 Business Overview
                          • 16.1.2 Influenza Vaccines Portfolio
                          • 16.1.3 Influenza Vaccines Sales Value Analysis
                          • 16.1.4 Promising Influenza Vaccines in the Clinical Development
                          • 16.1.5 Recent Development
                        • 16.2 GlaxoSmithKline (GSK)
                          • 16.2.1 Business Overview
                          • 16.2.2 Influenza Vaccines Portfolio
                          • 16.2.3 Influenza Vaccines Sales Value Analysis
                          • 16.2.4 Recent Development
                        • 16.3 Seqirus
                          • 16.3.1 Business Overview
                          • 16.3.2 Influenza Vaccines Portfolio
                          • 16.3.3 Influenza Vaccines Sales Value Analysis
                          • 16.3.4 Promising Influenza Vaccines in the Clinical Development
                          • 16.3.5 Recent Development
                        • 16.4 AstraZeneca
                          • 16.4.1 Business Overview
                          • 16.4.2 Influenza Vaccines Portfolio
                          • 16.4.3 Influenza Vaccines Sales Value Analysis
                          • 16.4.4 Recent Development

                        17. Emerging Players

                        • 17.1 Novavax
                          • 17.1.1 Business Overview
                          • 17.1.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.1.3 Recent Development
                        • 17.2 BiondVax Pharmaceuticals Ltd.
                          • 17.2.1 Business Overview
                          • 17.2.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.2.3 Recent Development
                        • 17.3 Medicago
                          • 17.3.1 Business Overview
                          • 17.3.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.3.3 Recent Development
                        • 17.4 Moderna Inc
                          • 17.4.1 Business Overview
                          • 17.4.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.4.3 Recent Development
                        • 17.5 Pneumagen
                          • 17.5.1 Business Overview
                          • 17.5.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.5.3 Recent Development
                        • 17.6 Altimmune
                          • 17.6.1 Business Overview
                          • 17.6.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.6.3 Recent Development
                        • 17.7 Daiichi Sankyo
                          • 17.7.1 Business Overview
                          • 17.7.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.7.3 Recent Development
                        • 17.8 FluGen
                          • 17.8.1 Business Overview
                          • 17.8.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.8.3 Recent Development
                        • 17.9 Imutex
                          • 17.9.1 Business Overview
                          • 17.9.2 Promising Vaccines in the Clinical Development
                          • 17.9.3 Recent Development
                        • 17.10 EpiVax
                          • 17.10.1 Business Overview
                          • 17.10.2 Promising Influenza Vaccines in the Clinical Development
                          • 17.10.3 Recent Development
                        • 17.11 Versatope Therapeutics, Inc
                          • 17.11.1 Business Overview
                          • 17.11.2 Promising Influenza Vaccines in the Clinical Development

                        The United States influenza vaccines market size to cross US$ 5.5 Billion by 2028.

                        This new market report presents an inclusive study of the entire United States influenza vaccines market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides up–to–date market size data for the period 2015 – 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for influenza vaccines.

                        Some of the Major Factors Contributing to the Growth of the Market:

                        • The Surge in the COVID–19 Pandemic
                        • Increased Disease Awareness
                        • Introduction of the Quadrivalent Influenza Vaccines
                        • Increasing Research and Development
                        • Expanded Recommendations by Governmental and Advisory Bodies to be Vaccinated against Influenza Vaccines

                        Key Highlights:

                        • The United States Rises to Become Largest Influenza Vaccines Market
                        • The Demand for the Flu Vaccine is Expected to Increase in the Forecast Period Because of the COVID–19 Pandemic Surge
                        • EpiVax to Design Antigens for Next–Generation Flu Vaccine
                        • Versatope Therapeutics, Inc Awarded a Contract worth up to US$17.9 Million from the National Institute of Allergy and Infectious Diseases (NIAID)

                        This Comprehensive U.S Influenza Vaccines Report Provides:

                        • The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast
                        • Evaluates the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast
                        • Scrutinizes the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast
                        • Studies the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast
                        • Delivers Comprehensive Insights on the Latest Pricing Trends and Analysis
                        • Covers a Broad Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)
                        • Delivers a Complete Outline of the US Influenza Vaccines Distribution and Demand
                        • Studies the Latest Effectiveness of the Influenza Vaccines in the United States
                        • Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza
                        • Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States
                        • Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market
                        • Features Reimbursement Patterns of the United States Influenza Vaccines Market
                        • Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive, and Licensing Agreement
                        • An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development
                        • Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020
                        • Delivers an In–Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Influenza Vaccines Market
                        • A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolio, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
                        • An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

                        The Key and Emerging Market Players for the U.S Influenza Vaccines Market are Listed Below :

                        • Sanofi Pasteur
                        • GlaxoSmithKline (GSK)
                        • Seqirus (CSL Limited)
                        • AstraZeneca
                        • EpiVax, Inc
                        • Novavax
                        • Medicago
                        • Moderna Inc
                        • Pneumagen
                        • Daiichi–Sankyo
                        • Altimmune
                        • FluGen
                        • Imutex
                        • Versatope Therapeutics, Inc
                        • BiondVax Pharmaceuticals Ltd.

                        Key Questions Answered in this Report:

                        • What is the current scenario of the U.S. influenza vaccines market?
                        • What is the total market size and forecast (until 2028) for the U.S. influenza vaccines market?
                        • How many persons being vaccinated with influenza vaccines in the US during 2015 – 2028?
                        • How effective is influenza(flu) shot for 2020?
                        • What percentage of the United States do people get the flu vaccine?
                        • What are the key marketed influenza vaccines available in the United States?
                        • What are the major drivers of the United States influenza vaccines market?
                        • What are the major inhibitors of the United States influenza vaccines market?
                        • What is the reimbursement pattern in the United States influenza vaccines market?
                        • What is the regulatory framework in the United States influenza vaccines market?
                        • What are the major deals and agreement happenings in the United States influenza vaccines market?
                        • What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
                        • Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
                        • Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
                        • How is the market predicted to develop in the future?


                        Summary:
                        Get latest Market Research Reports on U.S. Influenza (Flu) Vaccines. Industry analysis & Market Report on U.S. Influenza (Flu) Vaccines is a syndicated market report, published as U.S. Influenza (Flu) Vaccines Market – Growth, Demand, Trends, Opportunity, Forecasts (2021 – 2028). It is complete Research Study and Industry Analysis of U.S. Influenza (Flu) Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                        Last updated on

                        REPORT YOU MIGHT BE INTERESTED

                        Purchase this Report

                        $2,500.00
                        $4,000.00
                        $4,000.00
                        1,827.50
                        2,924.00
                        2,924.00
                        2,152.50
                        3,444.00
                        3,444.00
                        283,950.00
                        454,320.00
                        454,320.00
                        188,075.00
                        300,920.00
                        300,920.00
                        Credit card Logo

                        Related Reports


                        Reason to Buy

                        Request for Sample of this report